- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05499832
Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions (TECNO)
March 28, 2023 updated by: University Hospital Inselspital, Berne
TECNO is a multicenter, prospective, randomized, open label, blinded endpoint (PROBE) proof-of-concept trial evaluating if additional administration of intra-arterial Tenecteplase (TNK) improves reperfusion in patients with incomplete mechanical thrombectomy (MT).
For this purpose, 156 adult participants experiencing an acute ischemic stroke due to a large vessel occlusion with incomplete reperfusion with residual occlusions after MT will be randomly assigned to receive 3mg intra-arterial (IA) TNK or best medical treatment.
Recruitment will occur at 20 academic tertiary stroke care centers in Switzerland, Spain, Belgium, and Germany and patients are followed up for 90 days after the index event.
Showing superiority for reperfusion outcomes would have a major impact on the future management of stroke patients.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
156
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Urs Fischer, Prof
- Phone Number: +41 61 328 45 09
- Email: urs.fischer@insel.ch
Study Contact Backup
- Name: Seraina Martina Beyeler, PhD
- Phone Number: +41316323970
- Email: nctu@insel.ch
Study Locations
-
-
-
Basel, Switzerland
- Recruiting
- Universitatsspital Basel
-
Contact:
- Marios Psychogios, Prof.
- Email: marios.Psychogios@usb.ch
-
Principal Investigator:
- Marios Psychogios, Prof
-
Bern, Switzerland, 3010
- Recruiting
- Universitätsspital Bern
-
Contact:
- Seraina Beyeler, PhD
- Phone Number: +41316323970
- Email: seraina.beyeler@insel.ch
-
Contact:
- Email: nctu@insel.ch
-
Principal Investigator:
- Jan Gralla, Prof
-
Genève, Switzerland, 1211
- Not yet recruiting
- Hôpitaux universitaires de Genève
-
Contact:
- Emmanuel Carrera, Dr
- Phone Number: +41 79 553 38 14
- Email: emmanuel.carrera@hcuge.ch
-
Contact:
- Paolo Machi, Prof
- Email: paolo.machi@hcuge.ch
-
Principal Investigator:
- Emmanuel Carrera, Dr
-
Lugano, Switzerland, 6900
- Not yet recruiting
- Ospedale Regionale di Lugano
-
Contact:
- Cianfoni Alessandro, Dr
-
Contact:
- Zara Hassan
-
Principal Investigator:
- Alessandro Cianfoni, Dr
-
St.Gallen, Switzerland, 9007
- Not yet recruiting
- Kantonsspital St.Gallen
-
Contact:
- Pasquale Mordasini, Prof
-
Contact:
- Vjosa Iljazi
-
Principal Investigator:
- Pasquale Mordasini, Prof
-
Zürich, Switzerland, 8091
- Recruiting
- Universitatsspital Zurich
-
Contact:
- Zsolt Kulcsar, Dr
- Email: zsolt.kulcsar@usz.ch
-
Contact:
- Elizabeth Rose
- Email: elizabeth.rose@usz.ch
-
Principal Investigator:
- Zsolt Kulcsar, Dr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Informed consent
- Age ≥18 years
- Clinical signs consistent with an acute ischemic stroke
- Patient had an initial large vessel occlusion in the anterior circulation defined as intracranial ICA, M1 or M2.
- Patient has undergone endovascular stroke treatment
- Onset to randomization no later than < 345 minutes after symptom-onset/last-seen well.
Incomplete reperfusion defined as
- For ICA/M1: TICI2b/2c (50-99%) reperfusion after endovascular treatment without mechanically amendable target-occlusion (as per definition by the interventionalist).
- For M2: TICI2a/2b/2c (1-99%) reperfusion after endovascular treatment without mechanically amendable target-occlusion (as per definition by the interventionalist).
- ICA/M1/M2 with TICI3 reperfusion (MCA territory) but emboli to the ACA territory without mechanically amendable target-occlusion (as per definition by the interventionalist).
- Signs of early ischemic changes of non-contrast CT Alberta Stroke Program Early CT Score (ASPECTS) ≥5 (for DWI-ASPECTS ≥ 4, for DWI-ASECTS: a region must have diffusion abnormality in 20% or more of its volume to be considered DWI-ASPECTS positive)
Exclusion Criteria
- Acute intracranial hemorrhage
- Contraindication to MRI (e.g. pacemaker)
- Patients with both, anterior and middle cerebral artery embolizations during the procedure
- Tandem occlusion requiring cervical stenting
- Any severe bleeding within the past 6 months
- Major surgery in the past 2 months
- Intake of direct oral anticoagulants <12h or Vitamin K Antagonist with INR >1.3
- Platelets < 50,000
- Non-controlled hypertension (defined as SBP >185 mmHg or DBP >110 mmHg refractory to treatment)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Best Medical Treatment (standard of care)
Patients will receive standard of care as per current ESO guidelines.
|
|
Experimental: Intra-arterial Tenecteplase
Patients will receive intra-arterial administration of Tenecteplase using a standard approved microcatheter.
|
Patients randomized to IA treatment will receive IA TNK via a standard approved microcatheter positioned as close as possible to the residual occlusion site or as distal as possible in the originating vessel if multiple residual occlusions exists.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early reperfusion of the residual intracranial occlusion(s)
Time Frame: 25 minutes after randomization
|
Defined by reperfusion improvement on angiography images
|
25 minutes after randomization
|
Late reperfusion of the residual intracranial occlusion(s)
Time Frame: 24 hours ±6 hours
|
Defined by complete reperfusion on perfusion imaging
|
24 hours ±6 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Degree of disability or dependence assessed by the modified ranking scale (mRS) (shift analysis)
Time Frame: 90 days+/-15 days
|
mRS
|
90 days+/-15 days
|
Normalized change in National Institute of Health Score Scale (NIHSS)
Time Frame: 24 hours +/- 6 hours post-randomization
|
NIHSS
|
24 hours +/- 6 hours post-randomization
|
Change in National Institute of Health Score Scale (NIHSS)
Time Frame: 90 days +/- 15 days post-randomization
|
NIHSS
|
90 days +/- 15 days post-randomization
|
Quality of life as assessed by the EuroQol 5D-3L (EQ-5D-3L)
Time Frame: 90 days +/- 15 days
|
EuroQol 5D-3L
|
90 days +/- 15 days
|
All-cause mortality
Time Frame: 90 days
|
Mortality
|
90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Urs Fischer, PhD, NCTU
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 21, 2023
Primary Completion (Anticipated)
July 31, 2025
Study Completion (Anticipated)
October 31, 2025
Study Registration Dates
First Submitted
April 26, 2022
First Submitted That Met QC Criteria
August 11, 2022
First Posted (Actual)
August 12, 2022
Study Record Updates
Last Update Posted (Actual)
March 29, 2023
Last Update Submitted That Met QC Criteria
March 28, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-00388
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Tenecteplase
-
Kaiser PermanenteGenentech, Inc.TerminatedPleural EffusionUnited States
-
Huashan HospitalShanghai 10th People's Hospital; Shanghai East Hospital; The Second Affiliated... and other collaboratorsCompleted
-
Boehringer IngelheimTerminatedHeart ArrestGermany, Belgium, Sweden, France, Austria, Italy, Norway, Spain, Switzerland
-
Genentech, Inc.CompletedDysfunctional Central Venous Access Catheters
-
The George InstituteUniversity of Calgary; Berry ConsultantsNot yet recruiting
-
University Of PerugiaTerminated
-
Genentech, Inc.CompletedDysfunctional Hemodialysis Catheters
-
Genentech, Inc.CompletedDysfunctional Central Venous Access Catheters
-
General Hospital of Shenyang Military RegionCompleted
-
Second Affiliated Hospital of Guangxi Medical UniversityCSPC Pharmaceutical Group LimitedNot yet recruiting